HPK1 inhibitors - Pipeline Insight, 2026

This “HPK1 inhibitors - Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in HPK1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

HPK1 inhibitors: Understanding

HPK1 inhibitors: Overview

HPK1 inhibitors are a class of emerging immunomodulatory drugs targeting hematopoietic progenitor kinase-1 (HPK1), a serine/threonine kinase belonging to the MAP4K family that is predominantly expressed in hematopoietic cells. HPK1 acts as a negative regulator of immune cell signaling, particularly in T cells, B cells, and dendritic cells, where it suppresses immune activation and contributes to immune tolerance. Because of this role, HPK1 has become an important target in cancer immunotherapy, as inhibiting this kinase can restore immune function and enhance anti-tumor responses.

HPK1 inhibitors are generally small-molecule kinase inhibitors designed to interact with the ATP-binding pocket of the HPK1 kinase domain. HPK1 itself contains an N-terminal kinase domain, proline-rich regions for protein-protein interactions, and a C-terminal regulatory domain. The kinase domain includes conserved structural elements such as a glycine-rich loop, hinge region, and a gatekeeper residue that are critical for inhibitor binding. Most HPK1 inhibitors are structurally optimized scaffolds (such as pyrimidine, indazole, or azaindoline derivatives) that selectively occupy this ATP-binding site, thereby blocking phosphorylation activity.

HPK1 inhibitors act by releasing the inhibitory brake on immune signaling pathways. Under normal physiological conditions, HPK1 negatively regulates T-cell receptor (TCR) signaling by destabilizing key adaptor proteins (such as SLP-76) and suppressing downstream MAPK signaling cascades. This leads to reduced cytokine production and limited immune cell activation. By inhibiting HPK1, these drugs enhance T-cell activation, proliferation, and cytokine secretion, and can also modulate other immune cells such as natural killer cells and dendritic cells, thereby strengthening the overall immune response.

HPK1 inhibitors bind to and inhibit the kinase activity of HPK1, thereby blocking HPK1-mediated immunosuppressive signaling pathways. This prevents HPK1 from suppressing TCR signaling, resulting in restoration of effector T-cell function and increased cytotoxic T-lymphocyte (CTL) activity against tumor cells. Additionally, inhibition of HPK1 can reduce the immunosuppressive tumor microenvironment by normalizing cytokine signaling and enhancing anti-tumor immunity. These combined effects make HPK1 inhibitors promising agents in oncology, particularly as part of combination immunotherapy strategies. HPK1 inhibitors represent a novel class of targeted immunotherapies that work by structurally binding to the kinase domain of HPK1 and functionally reversing immune suppression, thereby enhancing anti-tumor immune responses.

"HPK1 inhibitors- Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HPK1 inhibitors pipeline landscape is provided which includes the disease overview and HPK1 inhibitors treatment guidelines. The assessment part of the report embraces, in depth HPK1 inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HPK1 inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence HPK1 inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve HPK1 inhibitors.

HPK1 inhibitors Emerging Drugs Chapters

This segment of the HPK1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HPK1 inhibitors Emerging Drugs

• CFI-402411: Treadwell Therapeutics

CFI-402411 is an investigational small-molecule HPK1 inhibitor developed by Treadwell Therapeutics for cancer immunotherapy. This involves inhibition of HPK1 (MAP4K1), which enhances T-cell activation and promotes anti-tumor immune responses. It is being developed for the treatment of advanced solid tumors, particularly in patients with refractory or metastatic cancers. Currently, CFI-402411 is in Phase I/II clinical development evaluating safety and preliminary efficacy in cancer patients.

• BGB-26808: BeOne Medicines

BGB-26808 is an investigational small-molecule drug developed by BeOne Medicines, it is a potent and selective HPK1 inhibitor designed for cancer immunotherapy. Its mechanism of action involves inhibition of hematopoietic progenitor kinase-1 (HPK1), a negative regulator of T-cell activation, thereby enhancing immune responses against tumors. The drug is being developed for the treatment of advanced solid tumors, both as monotherapy and in combination with the anti-PD-1 antibody tislelizumab. Currently, BGB-26808 is in Phase I clinical development in an ongoing first-in-human study evaluating safety, tolerability, and preliminary efficacy.

• ARV-6723: Arvinas:

ARV-6723 is an investigational oral PROTAC degrader developed by Arvinas, designed to target hematopoietic progenitor kinase 1 (HPK1), and represents the company’s first immuno-oncology clinical candidate. Its mechanism of action involves selective degradation of HPK1, a negative regulator of T-cell receptor signaling, thereby enhancing immune activation and promoting anti-tumor responses. The drug is being developed for the treatment of advanced solid tumors, where preclinical studies have shown strong anti-tumor immune activity both as a single agent and in combination with immunotherapies. In terms of historical development, ARV-6723 has so far demonstrated robust preclinical efficacy and immunomodulatory activity, supporting its progression toward clinical evaluation. Currently, ARV-6723 is in the preclinical stage of development for the treatment of advanced solid tumors.

HPK1 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different HPK1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in HPK1 inhibitors

There are approx. 8+ key companies which are developing the therapies HPK1 inhibitors. The companies which have their HPK1 inhibitors drug candidates in the most advanced stage, i.e. Phase I/II include, Treadwell Therapeutics, and others.

Phases

The report covers around 10+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

HPK1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as:

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HPK1 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HPK1 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HPK1 inhibitors drugs.

HPK1 inhibitors Report Insights

• HPK1 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

HPK1 inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing HPK1 inhibitors drugs?
• How many HPK1 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HPK1 inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HPK1 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for HPK1 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Treadwell Therapeutics
• Stonewise Technology
• BeOne Medicines
• Arvinas:

Key Products

• CFI 402411
• SWA 1211
• BGB-26808
• BGB-15025
• ARV-6723

This product will be delivered within 2 business days.